Dataset Information


ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity.

ABSTRACT: Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade therapy is able to induce long-lasting antitumor responses in a fraction of cancer patients. Nonetheless, there is still room for improvement in the quest for new therapeutic combinations. ICOS costimulation has been underscored as a possible target to include with CTLA-4 blocking treatment. Herein, we describe an ICOS agonistic aptamer that potentiates T cell activation and induces stronger antitumor responses when locally injected at the tumor site in combination with anti-CTLA-4 antibody in different tumor models. Furthermore, ICOS agonistic aptamer was engineered as a bi-specific tumor-targeting aptamer to reach any disseminated tumor lesions after systemic injection. Treatment with the bi-specific aptamer in combination with CTLA-4 blockade showed strong antitumor immunity, even in a melanoma tumor model where CTLA-4 treatment alone did not display any significant therapeutic benefit. Thus, this work provides strong support for the development of combinatorial therapies involving anti-CTLA-4 blockade and ICOS agonist tumor-targeting agents.

SUBMITTER: Soldevilla MM 

PROVIDER: S-EPMC6838990 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4004958 | BioStudies
2020-01-01 | S-EPMC7514066 | BioStudies
1000-01-01 | S-EPMC3188744 | BioStudies
1000-01-01 | S-EPMC4840227 | BioStudies
1000-01-01 | S-EPMC4910717 | BioStudies
2017-01-01 | S-EPMC5316835 | BioStudies
2015-01-01 | S-EPMC4628789 | BioStudies
1000-01-01 | S-EPMC5502823 | BioStudies
2013-01-01 | S-EPMC4636341 | BioStudies
2018-01-01 | S-EPMC5821198 | BioStudies